$TGTX
TG THERAPEUTICS, INC.

2013 Q4 Form 10-K Financial Statement

#000114420415016369 Filed on March 16, 2015

View on sec.gov

Income Statement

Concept 2013 Q4 2013
Revenue $40.00K $152.4K
YoY Change 100.0% 699.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.460M $6.660M
YoY Change -4.58% 39.33%
% of Gross Profit
Research & Development $3.760M $13.66M
YoY Change 248.15% -35.03%
% of Gross Profit
Depreciation & Amortization $0.00 $1.127K
YoY Change 379.57%
% of Gross Profit
Operating Expenses $5.210M $23.12M
YoY Change 99.62% -14.1%
Operating Profit -$22.97M
YoY Change -14.61%
Interest Expense $2.200M $952.9K
YoY Change 323.08% 5.21%
% of Operating Profit
Other Income/Expense, Net $110.0K $2.488M
YoY Change 138.72%
Pretax Income -$5.660M -$20.48M
YoY Change 78.55% -20.79%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.660M -$20.48M
YoY Change 63.58% 13.31%
Net Earnings / Revenue -14150.0% -13438.82%
Basic Earnings Per Share
Diluted Earnings Per Share -$192.0K -$806.0K
COMMON SHARES
Basic Shares Outstanding 33.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.50M $40.50M
YoY Change 145.45% 145.45%
Cash & Equivalents $40.49M $600.0K
Short-Term Investments
Other Short-Term Assets $47.80K $1.700M
YoY Change 64.12% -15.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $42.30M $42.30M
YoY Change 128.96% 128.65%
LONG-TERM ASSETS
Property, Plant & Equipment $5.718K $0.00
YoY Change 391.24%
Goodwill $799.4K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $4.900M $4.900M
YoY Change
Other Assets $85.12K $100.0K
YoY Change
Total Long-Term Assets $5.809M $5.800M
YoY Change 61.45% 61.11%
TOTAL ASSETS
Total Short-Term Assets $42.30M $42.30M
Total Long-Term Assets $5.809M $5.800M
Total Assets $48.11M $48.10M
YoY Change 117.96% 117.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.800M $4.800M
YoY Change 336.36% 336.36%
Accrued Expenses $700.0K $700.0K
YoY Change 133.33% 133.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $700.0K $700.0K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $6.317M $6.300M
YoY Change 185.06% 186.36%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $100.0K
YoY Change -96.0% -96.0%
Other Long-Term Liabilities $1.700M $1.700M
YoY Change -5.56% -5.56%
Total Long-Term Liabilities $1.800M $1.800M
YoY Change -58.14% -58.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.317M $6.300M
Total Long-Term Liabilities $1.800M $1.800M
Total Liabilities $8.058M $8.100M
YoY Change 23.52% 24.62%
SHAREHOLDERS EQUITY
Retained Earnings -$39.40M
YoY Change
Common Stock $34.34K
YoY Change 32.98%
Preferred Stock
YoY Change
Treasury Stock (at cost) $234.3K
YoY Change 177.2%
Treasury Stock Shares 41.31K shares
Shareholders Equity $40.10M $40.10M
YoY Change
Total Liabilities & Shareholders Equity $48.11M $48.10M
YoY Change 117.96% 117.65%

Cashflow Statement

Concept 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$5.660M -$20.48M
YoY Change 63.58% 13.31%
Depreciation, Depletion And Amortization $0.00 $1.127K
YoY Change 379.57%
Cash From Operating Activities -$4.820M -$10.74M
YoY Change 473.81% 106.94%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $5.681K
YoY Change 306.08%
Acquisitions
YoY Change
Other Investing Activities -$4.920M -$4.920M
YoY Change
Cash From Investing Activities -$4.930M -$4.930M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$37.50M
YoY Change -44456.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 39.69M
YoY Change -150.0% 233.53%
NET CHANGE
Cash From Operating Activities -4.820M -10.74M
Cash From Investing Activities -4.930M -4.930M
Cash From Financing Activities 40.00K 39.69M
Net Change In Cash -9.710M 24.02M
YoY Change 955.43% 257.97%
FREE CASH FLOW
Cash From Operating Activities -$4.820M -$10.74M
Capital Expenditures -$10.00K $5.681K
Free Cash Flow -$4.810M -$10.75M
YoY Change 472.62% 106.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6317178 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40485466 USD
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10618584 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55713784 USD
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
23062034 USD
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
27169 USD
CY2014Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
85516 USD
CY2013Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
1742824 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
137101 USD
CY2013Q4 us-gaap Assets
Assets
48112390 USD
CY2014Q4 us-gaap Assets
Assets
86746890 USD
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
677778 USD
CY2014Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
6179743 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
47804 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
173952 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
42303263 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
85215029 USD
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
4918897 USD
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5718 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20357 USD
CY2013Q4 us-gaap Goodwill
Goodwill
799391 USD
CY2014Q4 us-gaap Goodwill
Goodwill
799391 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
85121 USD
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
275190 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4764502 USD
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3991625 USD
CY2013Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
532500 USD
CY2014Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
702000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
152381 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
152381 USD
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
190017 USD
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5121196 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1676191 USD
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1523810 USD
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
64529 USD
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
CY2013Q4 us-gaap Liabilities
Liabilities
8057898 USD
CY2014Q4 us-gaap Liabilities
Liabilities
6645006 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
34336 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
44974 USD
CY2013Q4 tgtx Contingently Issuable Shares
ContingentlyIssuableShares
6 USD
CY2014Q4 tgtx Contingently Issuable Shares
ContingentlyIssuableShares
6 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79658490 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
175476521 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234337 USD
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234337 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39404003 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95185280 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40054492 USD
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80101884 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48112390 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
86746890 USD
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8890796 shares
CY2014 tgtx Period Anticipated Sufficient To Fund Operating Cash Flow
PeriodAnticipatedSufficientToFundOperatingCashFlow
P24M
CY2014Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
275190 USD
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2479098 USD
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
554069 USD
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12364537 USD
CY2013Q4 us-gaap Cash
Cash
39931397 USD
CY2014Q4 us-gaap Cash
Cash
43349247 USD
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
64529 USD
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
275190 USD
CY2013Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
64529 USD
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
78861334 USD
CY2014 tgtx Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
less than three months
CY2013 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
886382 USD
CY2014 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
930701 USD
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-3300951 USD
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-720040 USD
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
64529 USD
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
275190 USD
CY2013Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.05 pure
CY2014Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.05 pure
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18614000 USD
CY2014Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
19544720 USD
CY2011Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3287700 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46904 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
46000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
313 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
397 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46591 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
194 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
194 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
61.08
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.40
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2249.85
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4457.57
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.37
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
971.70
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
971.70
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M8D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y6M
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 tgtx Warrant Or Right Aggregate Intrinsic Value
WarrantOrRightAggregateIntrinsicValue
14563539 USD
CY2013Q4 tgtx Warrant Or Right Aggregate Intrinsic Value
WarrantOrRightAggregateIntrinsicValue
14809030 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34336235 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44974248 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34294926 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44932939 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309 shares
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6614243 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
944464 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
982793 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
523750 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1616749 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7034957 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6400001 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.49
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.13
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.55
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
2.48
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
6.53
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
6.60
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.60
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.86
CY2013 tgtx Warrant Or Right Issued
WarrantOrRightIssued
0 shares
CY2014 tgtx Warrant Or Right Issued
WarrantOrRightIssued
0 shares
CY2013 tgtx Warrant Or Right Exercised
WarrantOrRightExercised
1018068 shares
CY2014 tgtx Warrant Or Right Exercised
WarrantOrRightExercised
1560826 shares
CY2013 tgtx Warrant Or Right Expired
WarrantOrRightExpired
43992 shares
CY2014 tgtx Warrant Or Right Expired
WarrantOrRightExpired
9893 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5718947 shares
CY2012Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
1.58
CY2013 tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
0
CY2014 tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
0
CY2013 tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
2.25
CY2014 tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
2.28
CY2013 tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
16.26
CY2014 tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
20.74
CY2013Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
1.34
CY2014Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
0.94
CY2013 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
1041519 USD
CY2014Q4 tgtx Warrant Or Right Aggregate Intrinsic Value
WarrantOrRightAggregateIntrinsicValue
61792184 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
5203148 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
21105292 USD
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15500000 USD
CY2014 tgtx Stock Issued During Period Shares New Issues Shelf Registration Statement
StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement
317000000 USD
CY2013Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5700000 shares
CY2013Q3 us-gaap Share Price
SharePrice
6.15
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48900000 USD
CY2013Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35000000 USD
CY2013Q3 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
37600000 USD
CY2013Q3 tgtx Underwriting Discounts And Offering Expenses
UnderwritingDiscountsAndOfferingExpenses
2700000 USD
CY2013Q4 us-gaap Notes Payable
NotesPayable
742307 USD
CY2014Q4 us-gaap Notes Payable
NotesPayable
275190 USD
CY2010Q1 tgtx Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt
PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt
0.5 pure
CY2013Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
190017 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
1829000 USD
CY2014Q4 us-gaap Deferred Revenue
DeferredRevenue
1676000 USD
CY2014 tgtx Additional Amount Receivable On Achievement Of Pre Specified Milestones
AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones
5000000 USD
CY2013 us-gaap Licenses Revenue
LicensesRevenue
152381 USD
CY2014 us-gaap Licenses Revenue
LicensesRevenue
152381 USD
CY2013 tgtx Non Cash Stock Expense
NonCashStockExpense
0 USD
CY2014 tgtx Non Cash Stock Expense
NonCashStockExpense
5350094 USD
CY2014 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
8731566 USD
CY2013 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
12621161 USD
CY2014 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
26004687 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13662680 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40086347 USD
CY2013 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
4161629 USD
CY2014 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
12373726 USD
CY2013 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
2496461 USD
CY2014 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
3413400 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6658090 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15787126 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
23118370 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
55873473 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-22965989 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-55721092 USD
CY2013 us-gaap Interest Income Other
InterestIncomeOther
30822 USD
CY2014 us-gaap Interest Income Other
InterestIncomeOther
55049 USD
CY2013 us-gaap Other Income
OtherIncome
108894 USD
CY2014 us-gaap Other Income
OtherIncome
95427 USD
CY2013 us-gaap Interest Expense
InterestExpense
952888 USD
CY2014 us-gaap Interest Expense
InterestExpense
930701 USD
CY2013 tgtx Change In Fair Value Of Non Current Note Payable
ChangeInFairValueOfNonCurrentNotePayable
3300951 USD
CY2014 tgtx Change In Fair Value Of Non Current Note Payable
ChangeInFairValueOfNonCurrentNotePayable
720040 USD
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2487779 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-60185 USD
CY2013 us-gaap Profit Loss
ProfitLoss
-20478210 USD
CY2014 us-gaap Profit Loss
ProfitLoss
-55781277 USD
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25413964 shares
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34068926 shares
CY2014 tgtx Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3556624 USD
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2014 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37648280 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16791408 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15550301 USD
CY2013 tgtx Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2280773 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5203148 USD
CY2013 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
27169 USD
CY2014 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
58347 USD
CY2013 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
4034605 USD
CY2014 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-603377 USD
CY2013 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
66506 USD
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5350093 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2664970 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1344440 USD
CY2013 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 USD
CY2014 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
95427 USD
CY2013 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
0 USD
CY2014 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
5350094 USD
CY2013 us-gaap Depreciation
Depreciation
1127 USD
CY2014 us-gaap Depreciation
Depreciation
3931 USD
CY2013 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
975 USD
CY2014 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
193581 USD
CY2013 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
2414569 USD
CY2014 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-210661 USD
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-229258 USD
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4563067 USD
CY2014 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-94590 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152381 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152381 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10739110 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35059919 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5681 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18570 USD
CY2013 tgtx Payments To Acquire Held To Maturity Securities Long Term
PaymentsToAcquireHeldToMaturitySecuritiesLongTerm
4919871 USD
CY2014 tgtx Payments To Acquire Held To Maturity Securities Long Term
PaymentsToAcquireHeldToMaturitySecuritiesLongTerm
0 USD
CY2013 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
0 USD
CY2014 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
18336719 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4925552 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18355289 USD
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2280773 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3556624 USD
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
677778 USD
CY2013 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
37648280 USD
CY2014 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
65614260 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
39694133 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
68643526 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24029471 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15228318 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16455995 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
202400 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
202400 USD
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1101572 USD
CY2014 tgtx Stock Issued During Period Value Market Public Offering
StockIssuedDuringPeriodValueMarketPublicOffering
48822852 USD
CY2014 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
4850055 shares
CY2014 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
50000000 USD
CY2014Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10.31
CY2013 tgtx Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
2797600 USD
CY2014 tgtx Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0 USD
CY2013Q4 tgtx Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
2797600 USD
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
149799 USD
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2797600 USD
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
575012 USD
CY2013 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
85121 USD
CY2014 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
51980 USD
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">USE OF ESTIMATES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
600000 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32399879 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
52350293 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2266167 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3358934 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
10971912 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
12417815 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
956727 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
69083769 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
69083769 USD
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20478210 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-55781277 USD
CY2013 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-6962592 USD
CY2014 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-18965634 USD
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-917810 USD
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2533156 USD
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
250000 USD
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1092767 USD
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
43026 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
35459 USD
CY2013 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-1924558 USD
CY2014 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-244814 USD
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10011934 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22800912 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 tgtx Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
2034
CY2013Q3 tgtx Stock Issued During Period Shares New Issues Over Allotments
StockIssuedDuringPeriodSharesNewIssuesOverAllotments
855000 shares
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
575012 USD
CY2013 tgtx Stock Issued During Period Value Exercise Of Warrants Cash Less
StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess
-1 USD
CY2013 tgtx Treasury Stock Value During Peirod
TreasuryStockValueDuringPeirod
-149799 USD
CY2014 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0 USD
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>CREDIT RISK</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-15-016369-index-headers.html Edgar Link pending
0001144204-15-016369-index.html Edgar Link pending
0001144204-15-016369.txt Edgar Link pending
0001144204-15-016369-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20141231.xml Edgar Link completed
tgtx-20141231.xsd Edgar Link pending
tgtx-20141231_cal.xml Edgar Link unprocessable
tgtx-20141231_def.xml Edgar Link unprocessable
tgtx-20141231_lab.xml Edgar Link unprocessable
tgtx-20141231_pre.xml Edgar Link unprocessable
tpg10.jpg Edgar Link pending
v403478_10k.htm Edgar Link pending
v403478_ex23-1.htm Edgar Link pending
v403478_ex31-1.htm Edgar Link pending
v403478_ex31-2.htm Edgar Link pending
v403478_ex32-1.htm Edgar Link pending
v403478_ex32-2.htm Edgar Link pending